Funding to stop Candida auris lacking

A high proportion of people who have been diagnosed with C. auris have died


Scientists who work in mycology — the study of fungi — say there is precious little money available to study Candida auris, according to an article on the STAT News website.

Candida auris is making news for its ability to resist multiple antifungal drugs and settle into hospital rooms so persistently it can take renovations to get rid of it.

The head of mycotic diseases at the Centers for Disease Control and Prevention (CDC) acknowledged his field hasn’t attracted the same kind of research dollars as other pathogens.

A high proportion of people who have been diagnosed with C. auris have died — the CDC estimates it’s between 30 percent and 60 percent.

Read the article.



July 16, 2019


Topic Area: Infection Control


Recent Posts

Disinfectant Dispensers in Healthcare Facilities Often Fail to Deliver Safe Concentrations: Study

Study of 10 hospitals finds 90 percent have at least one dispenser delivering disinfectants at incorrect concentrations.


Duke University Health System Receives $50 Million for Proton Beam Therapy Center

The donation is the largest philanthropic gift received by Duke University Health System.


UT Southwestern Experiences Data Breach Through Calendar Tool

The incident occurred in October.


Protecting Patient Data: Strategies and Tactics

As cyber threats and breaches grow, healthcare organizations and facilities need a better approach to cybersecurity.


Duke Health to Acquire Lake Norman Regional Medical Center

The closing is projected for the first quarter of 2025.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.